A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib

PVRI Member Authors: Vandana Seeram

Abstract

Dasatinib is a small-molecule tyrosine kinase inhibitor used in the treatment of hematological malignancies. Pulmonary arterial hypertension (PAH) is a rare but known complication. The mainstay of treatment is cessation of Dasatinib, and while clinical improvement is rapid, complete hemodynamic resolution of pulmonary hypertension (PH) still remains exceedingly uncommon. We present a case of Dasatinib-induced PAH in a woman with chronic myeloid leukemia, who demonstrated rapid and complete clinical and hemodynamic resolution following treatment with combination pulmonary vasodilator therapy using an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor. This case suggests there may be an association between the use of targeted PH medication in combination and the complete resolution of dasatinib-associated PAH, but further investigation is required.

Read the full article online

Topics

Pharmacology: Pharmacokinetics and Pharmacodynamics
Pulmonary Arterial Hypertension

Authors

Karan Seegobin, Amit Babbar, Jason Ferreira, Brittany Lyons, James Cury

Published in:

Pulmonary Circulation Vol 7: No 4 cover image

December 2017

Pulmonary Circulation Vol 7: No 4

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg